Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma

[1]  K. Nackaerts,et al.  Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Klabatsa,et al.  Chemotherapy options and new advances in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Robert M. White,et al.  Pemetrexed in malignant pleural mesothelioma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Scagliotti,et al.  Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Giaccone,et al.  Phase II trial of ZD0473 as second-line therapy in mesothelioma. , 2002, European journal of cancer.

[7]  G. Melloni,et al.  Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. , 2001, Lung cancer.

[8]  D. Sugarbaker,et al.  The α folate receptor is highly activated in malignant pleural mesothelioma , 2001 .

[9]  M. Fukushima,et al.  The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. , 2000, Current pharmaceutical biotechnology.

[10]  T. Vehmas,et al.  High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma , 1999, British Journal of Cancer.

[11]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[12]  A. Purohit,et al.  Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. , 1998, Lung cancer.

[13]  R M Schultz,et al.  LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. , 1997, Cancer research.

[14]  B. Price.  Analysis of current trends in United States mesothelioma incidence. , 1997, American journal of epidemiology.

[15]  V. Rusch.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.

[16]  M. J. van den Bent,et al.  Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[18]  N. Pavlakis,et al.  Second-Line Chemotherapy , 2005 .

[19]  R. V. van Klaveren,et al.  Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. , 2004, Lung cancer.

[20]  D. Sugarbaker,et al.  The alpha folate receptor is highly activated in malignant pleural mesothelioma. , 2001, The Journal of thoracic and cardiovascular surgery.

[21]  C. Ryan,et al.  A review of chemotherapy trials for malignant mesothelioma. , 1998, Chest.

[22]  J. Schornagel,et al.  Clinical pharmacokinetics of anti-metabolites. , 1993, Cancer surveys.

[23]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.